On Friday of last week Evolus drug Jeuveau gained approval from the FDA (Food and Drug Administration) of the United States of America.
This drug will for sure be the cheaper rival of Allergan’s Botox.
What does Jeuveau do? It removes wrinkle lines on the forehead and frown wrinkles. This is significant as Baby Boomers (people who are in or going to be retiring) try to retain a youthful look. No one wants to age.
I believe Allergan is in the process of suing Evolus to keep the drug off the market. However, they may not win as it has been approved and there is no patent on Botox, it is just trademarked the name I believe.
If this drug catches on due to being the cheaper alternative, we are talking about at least a $5 billion USD company which would be 800% gain from here. Right now Botox contributes over $3.2 billion USD in revenue to Allergan in 2017. Allergan is a $45 billion USD business and just in 2015 Allergan had a $100 billion USD valuation.
Right now the company is going for $26 USD a share. They have to change their business from drug exploration and development to a pharmaceutical company that has a sales force and distribution.
I have never invested in a pharmaceutical company and we will see how this develops over the next few years.
We will see where this goes but it definitely is positive for Evolus. Lets see where this goes.
You can find more articles about investing and the stock market over here http://www.thevalueswan.com
This material has been prepared by Thevalueswan.com . This document is for information and illustrative purposes only and does not purport to show actual results. It is not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action. Opinions expressed herein are current opinions as of the date appearing in this material only and are subject to change without notice. Reasonable people may disagree about the opinions expressed herein. In the event any of the assumptions used herein do not prove to be true, results are likely to vary substantially. All investments entail risks. There is no guarantee that investment strategies will achieve the desired results under all market conditions and each investor should evaluate its ability to invest for a long term especially during periods of a market downturn. No representation is being made that any account, product, or strategy will or is likely to achieve profits, losses, or results similar to those discussed, if any. No part of this document may be reproduced in any manner, in whole or in part, without the prior written permission of Thevalueswan.com , other than to your employees. This information is provided with the understanding that with respect to the material provided herein, that you will make your own independent decision with respect to any course of action in connection herewith and as to whether such course of action is appropriate or proper based on your own judgment, and that you are capable of understanding and assessing the merits of a course of action. Thevalueswan.com does not purport to and does not, in any fashion, provide broker/dealer, consulting or any related services. You may not rely on the statements contained herein. Thevalueswan.com shall not have any liability for any damages of any kind whatsoever relating to this material. You should consult your advisors with respect to these areas. By accepting this material, you acknowledge, understand and accept the foregoing.